Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

First-in-Human Trial of Novel Therapy Shows Promising Results in Relapsed/Refractory Multiple Myeloma

May 31st 2020

CC-92480, a novel cereblon E3 ligase modulator agent, in combination with dexamethasone appeared safe and active in patients with heavily pretreated relapsed or refractory multiple myeloma, according to data presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Adding Xpovio to Standard Drugs for Multiple Myeloma Delays Disease Progression and Reduces Neuropathy

May 31st 2020

The addition of the novel drug Xpovio to the regimen of Velcade and dexamethasone delayed disease progression, reduced peripheral neuropathy and required fewer office visits in a study of previously treated patients with multiple myeloma.

Standard of Care in Newly Diagnosed Myeloma Remains as Carfilzomib Triplet Does Not Improve Outcomes

May 30th 2020

New findings, presented at the 2020 ASCO Virtual Scientific Program, suggest that the standard of care for newly diagnosed patients with multiple myeloma remains as Kyprolis triplet does not improve outcomes.

Multiple Myeloma

May 6th 2020

Understanding multiple myeloma.

COVID-19's Impact on How Patients with CLL, Myeloma Have Received Treatment

May 4th 2020

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Farukh Awan addresses how the new coronavirus has impacted patient care for those diagnosed with chronic lymphocytic leukemia and myeloma.

FDA Approves Darzalex Faspro For Patients with Multiple Myeloma

May 1st 2020

The Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a subcutaneous form of Darzalex, for adults with newly diagnosed or relapsed/refractory multiple myeloma.

CURE's Clinical Trial Corner: April 2020

April 30th 2020

Here is a list of the recent trial initiations that occurred within the cancer space in April.

CURE Community Vlog: Winning Despite 'Being Dealt a Bad Hand' After Cancer

April 28th 2020

“Only you have the power to make your life better,” says a myeloma survivor on living for the moment after a cancer diagnosis.

Genetic Test May Identify Patients at Risk for Disease Progression with Multiple Myeloma

April 17th 2020

A new genetic test that identifies patients with multiple myeloma who have high-risk genetics may help oncologists find alternative treatment options before the disease progresses.

CURE Community Vlog: Finding Something Positive When Faced With Adversity

April 17th 2020

“I just want people to know that when they say you have cancer, they are not saying you have a death sentence. You can still live and you can live well.”

Melflufen, Dexamethasone Combination Appears Safe and Effective in Relapsed and Refractory Multiple Myeloma

April 15th 2020

Patients with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy experienced a durable clinical benefit after receiving melflufen (Oncopeptides) in combination with dexamethasone.

Helping with Support Groups

March 15th 2020

What You Need to Know About the FDA's Approval of Sarclisa for Multiple Myeloma

March 14th 2020

The Food and Drug Administration approved the targeted therapy Sarclisa for the treatment of patients with multiple myeloma. Here’s what you need to know.

Overcoming Multiple Myeloma Takes One Patient to New Heights

March 6th 2020

Terry White, who has lived with multiple myeloma for more than a decade, offers reassurance to other patients.

Laugh for Life

March 5th 2020

In this episode of the “CURE Talks Cancer” podcast, we spoke with the co-chair of the MMRF’s Laugh for Life event, as well as this year’s “Spirit of Hope” award recipient.

FDA Approves Sarclisa to Treat Multiple Myeloma

March 3rd 2020

The Food and Drug Administration approved Sarclisa, as adding the targeted drug to combination therapy delays the progression of multiple myeloma in previously treated patients.

The Use of Immunotherapy in Blood Cancer Treatment

February 7th 2020

Exciting Treatment Options Being Developed in Multiple Myeloma

February 7th 2020

Genetic Sequencing in Chronic Lymphocytic Leukemia

February 7th 2020

The Basics of Mantle Cell Lymphoma

February 7th 2020

Joining a Clinical Trial

February 7th 2020

Creating a Game Plan to Manage Multiple Myeloma

February 7th 2020

Patient Rod Gilmore shares his experience with multiple myeloma and the importance of creating a strategy to manage the disease.

Reflections On The Journey of Cancer and Marriage

January 30th 2020

FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma

January 21st 2020

The Food and Drug Administration granted a priority review to belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma.

Understanding the Key Aspects of a Multiple Myeloma Diagnosis

January 3rd 2020

A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.

Understanding Precision Medicine in Multiple Myeloma

January 2nd 2020

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Cesar Rodriguez about precision medicine, and his recent trek to Patagonia with Moving Mountains for Multiple Myeloma.

Precision Medicine Paves the Way for Exciting Treatment Combinations for Patients with Multiple Myeloma

December 25th 2019

Patients with multiple myeloma have a lot to look forward to in the treatment space thanks to precision medicine, but one treatment option alone will not cure the disease.

Coming to Grips with A Multiple Myeloma Diagnosis

December 21st 2019

At the 2019 CURE® Educated Patient® Summit on Multiple Myeloma patient advocate and 10-year survivor Terry White had the chance to share advice on handling a cancer diagnosis.

Addressing Questions From Newly Diagnosed Patients with Multiple Myeloma

December 20th 2019

Naturally, newly diagnosed patients with multiple myeloma have a lot of questions for their physicians. Dr. Joshua Richter had the time to discuss some of them.

Understanding the Role of Immunoglobulins in Multiple Myeloma

December 16th 2019

At CURE’s Educated Patient Summit on Multiple Myeloma Dr. Shebli Atrash had the chance to further discuss with CURE what questions he addresses most when patients with multiple myeloma undergo diagnostic testing.